200 related articles for article (PubMed ID: 25009136)
1. Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study.
Hughes S; Cohen D; Jaggi R
BMJ Open; 2014 Jul; 4(7):e005535. PubMed ID: 25009136
[TBL] [Abstract][Full Text] [Related]
2. Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles.
Tang E; Ravaud P; Riveros C; Perrodeau E; Dechartres A
BMC Med; 2015 Aug; 13():189. PubMed ID: 26269118
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Data on Serious Adverse Events and Mortality in ClinicalTrials.gov, Corresponding Journal Articles, and FDA Medical Reviews: Cross-Sectional Analysis.
Pradhan R; Singh S
Drug Saf; 2018 Sep; 41(9):849-857. PubMed ID: 29644579
[TBL] [Abstract][Full Text] [Related]
4. Clinical trials on drug-drug interactions registered in ClinicalTrials.gov reported incongruent safety data in published articles: an observational study.
Jurić D; Pranić S; Tokalić R; Milat AM; Mudnić I; Pavličević I; Marušić A
J Clin Epidemiol; 2018 Dec; 104():35-45. PubMed ID: 30081071
[TBL] [Abstract][Full Text] [Related]
5. Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications.
Hartung DM; Zarin DA; Guise JM; McDonagh M; Paynter R; Helfand M
Ann Intern Med; 2014 Apr; 160(7):477-83. PubMed ID: 24687070
[TBL] [Abstract][Full Text] [Related]
6. Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: A meta-analysis.
de Vries YA; Roest AM; Beijers L; Turner EH; de Jonge P
Eur Neuropsychopharmacol; 2016 Nov; 26(11):1752-1759. PubMed ID: 27659240
[TBL] [Abstract][Full Text] [Related]
7. Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis.
Ross JS; Mulvey GK; Hines EM; Nissen SE; Krumholz HM
PLoS Med; 2009 Sep; 6(9):e1000144. PubMed ID: 19901971
[TBL] [Abstract][Full Text] [Related]
8. Quality of reporting of adverse events in clinical trials of covid-19 drugs: systematic review.
Madi K; Flumian C; Olivier P; Sommet A; Montastruc F
BMJ Med; 2023; 2(1):e000352. PubMed ID: 37779893
[TBL] [Abstract][Full Text] [Related]
9. Serious Adverse Events Reporting in Phase III Randomized Clinical Trials of Colorectal Cancer Treatments: A Systematic Analysis.
Yao Y; Liu Z; Zhang H; Li J; Peng Z; Yu J; Cao B; Shen L
Front Pharmacol; 2021; 12():754858. PubMed ID: 34867369
[No Abstract] [Full Text] [Related]
10. Clinical trial design and dissemination: comprehensive analysis of clinicaltrials.gov and PubMed data since 2005.
Zwierzyna M; Davies M; Hingorani AD; Hunter J
BMJ; 2018 Jun; 361():k2130. PubMed ID: 29875212
[TBL] [Abstract][Full Text] [Related]
11. Patient reporting of sexual adverse events on an online platform for medication experiences.
Gordijn R; Wessels W; Kriek E; Nicolai MPJ; Elzevier HW; Visser L; Guchelaar HJ; Teichert M
Br J Clin Pharmacol; 2022 Dec; 88(12):5326-5335. PubMed ID: 35778921
[TBL] [Abstract][Full Text] [Related]
12. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review.
Beytout Q; Afach S; Guelimi R; Sbidian E; Le Cleach L
J Clin Epidemiol; 2024 May; ():111406. PubMed ID: 38825170
[TBL] [Abstract][Full Text] [Related]
13. Are antidepressant and antipsychotic drug trials registered? A cross-sectional analysis of registration and reporting of methodologic characteristics.
Shaw R; Ni M; Pillar M; Tejani AM
Account Res; 2018; 25(5):301-309. PubMed ID: 29879851
[TBL] [Abstract][Full Text] [Related]
14. Selective reporting bias in randomised controlled trials from two network meta-analyses: comparison of clinical trial registrations and their respective publications.
Wong EK; Lachance CC; Page MJ; Watt J; Veroniki A; Straus SE; Tricco AC
BMJ Open; 2019 Sep; 9(9):e031138. PubMed ID: 31492792
[TBL] [Abstract][Full Text] [Related]
15. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
[TBL] [Abstract][Full Text] [Related]
16. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study.
Prayle AP; Hurley MN; Smyth AR
BMJ; 2012 Jan; 344():d7373. PubMed ID: 22214756
[TBL] [Abstract][Full Text] [Related]
17. Outcome reporting among drug trials registered in ClinicalTrials.gov.
Bourgeois FT; Murthy S; Mandl KD
Ann Intern Med; 2010 Aug; 153(3):158-66. PubMed ID: 20679560
[TBL] [Abstract][Full Text] [Related]
18. Reporting of clinical trial safety results in ClinicalTrials.gov for FDA-approved drugs: A cross-sectional analysis.
Chen KY; Borglund EM; Postema EC; Dunn AG; Bourgeois FT
Clin Trials; 2022 Aug; 19(4):442-451. PubMed ID: 35482320
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Consistency Between Peer-Reviewed Publications and Clinical Trial Registries.
Sun LW; Lee DJ; Collins JA; Carll TC; Ramahi K; Sandy SJ; Unteriner JG; Weinberg DV
JAMA Ophthalmol; 2019 May; 137(5):552-556. PubMed ID: 30946427
[TBL] [Abstract][Full Text] [Related]
20. Completeness and consistency of primary outcome reporting in COVID-19 publications in the early pandemic phase: a descriptive study.
Stoll M; Lindner S; Marquardt B; Salholz-Hillel M; DeVito NJ; Klemperer D; Lieb K
BMC Med Res Methodol; 2023 Jul; 23(1):173. PubMed ID: 37516878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
